Design and discovery of 6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one (PF-04447943), a selective brain penetrant PDE9A inhibitor for the treatment of cognitive disorders.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Journal of Medicinal Chemistry

• Publication date

  2012-07-25

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1021/jm3007799PMID 22780914
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Phosphodiesterase 9A Regulates Central cGMP and Modulates Responses to Cholinergic and Monoaminergic Perturbation In Vivo

  2012cited by this paper
• Milrinone

  2012cited by this paper
• The Selective Phosphodiesterase 9 (PDE9) Inhibitor PF-04447943 Attenuates a Scopolamine-Induced Deficit in a Novel Rodent Attention Task

  2011cited by this paper
• The selective phosphodiesterase 9 (PDE9) inhibitor PF-04447943 (6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one) enhances synaptic plasticity and cognitive function in rodents.

  2011cited by this paper
• Phosphodiesterase inhibitors as potential cognition enhancing agents.

  2010cited by this paper
• O3‐05‐04: Safety and pharmacokinetics of PF‐04447943, a PDEA inhibitor, in single and multiple dose Phase 1 studies in healthy volunteers

  2010cited by this paper
• P3‐380: Dendritic spine density deficits in the hippocampal CA1 region of young Tg2576 mice are ameliorated with the PDE9A inhibitor PF‐04447943

  2010cited by this paper
• Defining desirable central nervous system drug space through the alignment of molecular properties, in vitro ADME, and safety attributes.

  2010cited by this paper
• Moving beyond rules: the development of a central nervous system multiparameter optimization (CNS MPO) approach to enable alignment of druglike properties.

  2010cited by this paper
• Identification of a brain penetrant PDE9A inhibitor utilizing prospective design and chemical enablement as a rapid lead optimization strategy.

  2009cited by this paper
• Discovery of a novel class of phosphodiesterase 10A inhibitors and identification of clinical candidate 2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline (PF-2545920) for the treatment of schizophrenia.

  2009cited by this paper
• P2‐239: Cell‐based ciliary neurotrophic factor therapy against Alzheimer's disease

  2009cited by this paper
• P2‐240: PF‐04447943, a novel PDE9A inhibitor, increases cGMP levels in cerebrospinal fluid: Translation from non‐clinical species to healthy human volunteers

  2009cited by this paper
• In Vitro P-glycoprotein Assays to Predict the in Vivo Interactions of P-glycoprotein with Drugs in the Central Nervous System

  2008cited by this paper
• The novel selective PDE9 inhibitor BAY 73-6691 improves learning and memory in rodents.

  2008cited by this paper
• Discovery of a series of 6,7-dimethoxy-4-pyrrolidylquinazoline PDE10A inhibitors.

  2007cited by this paper
• PDE4 inhibitors as potential therapeutic agents in the treatment of COPD-focus on roflumilast

  2007cited by this paper
• Phosphodiesterases in the CNS: targets for drug development

  2006cited by this paper
• A centralized approach to tandem mass spectrometry method development for high-throughput ADME screening.

  2006cited by this paper
• Amyloid-beta peptide inhibits activation of the nitric oxide/cGMP/cAMP-responsive element-binding protein pathway during hippocampal synaptic plasticity.

  2005cited by this paper
• Phosphodiesterase 5 Inhibitors for Erectile Dysfunction

  2005cited by this paper
• Amyloid-β Peptide Inhibits Activation of the Nitric Oxide/cGMP/cAMP-Responsive Element-Binding Protein Pathway during Hippocampal Synaptic Plasticity

  2005cited by this paper
• Structural basis for the activity of drugs that inhibit phosphodiesterases.

  2004cited by this paper
• Intravenous milrinone in treatment of advanced congestive heart failure.

  2003cited by this paper
• Expression of cGMP-Specific Phosphodiesterase 9A mRNA in the Rat Brain

  2001cited by this paper
• The maximal affinity of ligands.

  1999cited by this paper
• Nitric Oxide Signaling Contributes to Late-Phase LTP and CREB Phosphorylation in the Hippocampus

  1999cited by this paper
• Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes.

  1999cited by this paper
• Isolation and Characterization of PDE9A, a Novel Human cGMP-specific Phosphodiesterase*

  1998cited by this paper
• The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data.

  1997cited by this paper
• Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms.

  1995cited by this paper

• Magnetic Nanoparticle-Catalysed One-Pot Multicomponent Reactions (MCRs): A Green Chemistry Approach

  2025cites this paper
• Emerging phosphodiesterase inhibitors for treatment of neurodegenerative diseases

  2024cites this paper
• The therapeutic potential of phosphodiesterase 9 (PDE9) inhibitors: a patent review (2018-present)

  2024cites this paper
• Ultrasound Assisted Synthesis of Pyran Derivatives Catalysed by Uranyl Nitrate and Their Molecular Docking Against Glycogen Synthase Kinase-3 Beta Receptor

  2024cites this paper
• Visible light-induced organo-photocatalyzed route to synthesize substituted pyrazoles.

  2024cites this paper
• Virtual Screening-Accelerated Discovery of a Phosphodiesterase 9 Inhibitor with Neuroprotective Effects in the Kainate Toxicity In Vitro Model

  2023cites this paper
• An overview of phosphodiesterase 9 inhibitors: Insights from skeletal structure, pharmacophores, and therapeutic potential.

  2023cites this paper
• 8-Hydroxyquinolines: A Promising Pharmacophore Potentially Developed as Disease-Modifying Agents for Neurodegenerative Diseases: A Review

  2022cites this paper
• BAY-7081: A Potent, Selective, and Orally Bioavailable Cyanopyridone-Based PDE9A Inhibitor

  2022cites this paper
• Therapeutic potential of phosphodiesterase inhibitors for cognitive amelioration in Alzheimer's disease.

  2022cites this paper
• 3-[(1H-Benzo[d][1,2,3]triazol-1-yl)oxy]propyl 9-hydroxy-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)icosahydro-3aH-cyclopenta[a]chrysene-3a-carboxylate

  2022cites this paper
• A novel phosphodiesterase 9A inhibitor LW33 protects against ischemic stroke through the cGMP/PKG/CREB pathway.

  2022cites this paper
• Diversifying the xanthine scaffold for potential phosphodiesterase 9A inhibitors: synthesis and validation

  2021cites this paper
• Pyrazole Scaffold Synthesis, Functionalization, and Applications in Alzheimer’s Disease and Parkinson’s Disease Treatment (2011–2020)

  2021cites this paper
• Bicyclic 5–6 Systems: Other Four Heteroatoms 2:2

  2021cites this paper
• Correction to: Diversifying the xanthine scaffold for potential phosphodiesterase 9A inhibitors: synthesis and validation

  2021cites this paper
• Computational Study on Selective PDE9 Inhibitors on PDE9-Mg/Mg, PDE9-Zn/Mg, and PDE9-Zn/Zn Systems

  2021cites this paper
• Discovery of Potent Phosphodiesterase-9 Inhibitors for the Treatment of Hepatic Fibrosis.

  2021cites this paper
• Inhibition of phosphodiesterase type 9 reduces obesity and cardiometabolic syndrome in mice.

  2021cites this paper
• Inhibition of PDE2 and PDE4 synergistically improves memory consolidation processes.

  2020cites this paper
• Phosphodiesterase 9A Inhibition Facilitates Corticostriatal Transmission in Wild-Type and Transgenic Rats That Model Huntington’s Disease

  2020influential citation
• Design, synthesis and evaluation of pyrazolopyrimidinone derivatives as novel PDE9A inhibitors for treatment of Alzheimer's disease.

  2020cites this paper
• Late-stage synthesis and application of photoreactive probes derived from direct benzoylation of heteroaromatic C-H bonds.

  2020cites this paper
• Phosphodiesterase as a Target for Cognition Enhancement in Schizophrenia.

  2020cites this paper
• Multitarget Approach for the Treatment of Alzheimer`s Disease: Inhibition of Phosphodiesterase 9 (PDE9) and Histone Deacetylases (HDACs) covering diverse selectivity profiles.

  2019cites this paper
• Phosphodiesterase 9A in Brain Regulates cGMP Signaling Independent of Nitric-Oxide

  2019cites this paper
• Discovery of Potent, Selective, and Orally Bioavailable Inhibitors against Phosphodiesterase-9, a Novel Target for the Treatment of Vascular Dementia.

  2019cites this paper
• Design, synthesis and biological evaluation of pyrazolopyrimidinone based potent and selective PDE5 inhibitors for treatment of erectile dysfunction.

  2019cites this paper
• Increased building block access through collaboration.

  2018cites this paper
• PF‐04447943, a Phosphodiesterase 9A Inhibitor, in Stable Sickle Cell Disease Patients: A Phase Ib Randomized, Placebo‐Controlled Study

  2018cites this paper
• Prokaryotic Expression, Purification and Identification of Human PDE9A Protein

  2018cites this paper
• A novel PDE9 inhibitor WYQ‐C36D ameliorates corticosterone‐induced neurotoxicity and depression‐like behaviors by cGMP‐CREB‐related signaling

  2018cites this paper
• Novel Phosphodiesterase Inhibitors for Cognitive Improvement in Alzheimer's Disease.

  2018cites this paper
• Bridging Type 2 Diabetes and Alzheimer's Disease: Assembling the Puzzle Pieces in the Quest for the Molecules With Therapeutic and Preventive Potential

  2018cites this paper
• Furoxans (Oxadiazole-4 N-oxides) with Attenuated Reactivity are Neuroprotective, Cross the Blood Brain Barrier, and Improve Passive Avoidance Memory.

  2018cites this paper
• Elucidation of fluorine's impact on pKa and in vitro Pgp-mediated efflux for a series of PDE9 inhibitors.

  2018cites this paper
• Recent disclosures of clinical candidates: Highlights from the Society of Medicines Research Symposium. The National Heart and Lung Institute, London, U.K. - December 1, 2016

  2017influential citation
• Discovery of an Orally Bioavailable, Brain-Penetrating, in Vivo Active Phosphodiesterase 2A Inhibitor Lead Series for the Treatment of Cognitive Disorders.

  2017cites this paper
• Phosphodiesterase Inhibitors as a Therapeutic Approach to Neuroprotection and Repair

  2017influential citation
• C33(S), a novel PDE9A inhibitor, protects against rat cardiac hypertrophy through upregulating cGMP signaling

  2017cites this paper
• Application of Structure-Based Design and Parallel Chemistry to Identify a Potent, Selective, and Brain Penetrant Phosphodiesterase 2A Inhibitor.

  2017cites this paper
• Discovery of stimulator binding to a conserved pocket in the heme domain of soluble guanylyl cyclase

  2017cites this paper
• Novel Multitarget Hybrid Compounds for the Treatment of Alzheimer's Disease.

  2017cites this paper
• Discovery of novel PDE9A inhibitors with antioxidant activities for treatment of Alzheimer’s disease

  2017cites this paper
• Discovery of Selective Phosphodiesterase 1 Inhibitors with Memory Enhancing Properties.

  2017cites this paper
• Targeting Phosphodiesterases in the CNS

  2017cites this paper
• One-pot synthesis of pyran derivatives using silica-coated magnetic nanoparticles functionalized with piperidinium benzene-1,3-disulfonate as a new efficient reusable catalyst

  2017cites this paper
• Synthesis, Characterization, and Activity of a Triazine Bridged Antioxidant Small Molecule.

  2017cites this paper
• Discovery of novel PDE9 inhibitors capable of inhibiting Aβ aggregation as potential candidates for the treatment of Alzheimer’s disease

  2016cites this paper
• binding of a potent enantiomeric inhibitor

  2016cites this paper
• Selective inhibition of phosphodiesterases 4, 5 and 9 induces HSP20 phosphorylation and attenuates amyloid beta 1–42‐mediated cytotoxicity

  2016cites this paper
• Molecular dynamics-based discovery of novel phosphodiesterase-9A inhibitors with non-pyrazolopyrimidinone scaffolds.

  2015cites this paper
• DABCO-catalyzed synthesis of 3-bromo-/3-iodo-2H-pyrans from propargyl alcohols, dialkyl acetylene dicarboxylates, and N-bromo-/ N-iodosuccinimides

  2015cites this paper
• Phosphodiesterase 9A Controls Nitric-oxide Independent cGMP and Hypertrophic Heart Disease

  2015cites this paper
• The chemistry and biological activity of heterocycle-fused quinolinone derivatives: A review.

  2015cites this paper
• Structure-Based Discovery of PDEs Inhibitors.

  2015cites this paper
• Structural Asymmetry of Phosphodiesterase-9A and a Unique Pocket for Selective Binding of a Potent Enantiomeric Inhibitor

  2015cites this paper
• Phosphodiesterase 9: insights from protein structure and role in therapeutics.

  2014cites this paper
• Phosphodiesterase Inhibition in Cognitive Decline

  2014cites this paper
• Discovery of a Phosphodiesterase 9A Inhibitor as a Potential Hypoglycemic Agent

  2014cites this paper
• Investigation of new synthetic reactions: the synthesis of hydrazines via the Aza-Lossen rearrangement, the synthesis of carbamoyl azides from amines, and deprotection reactions using water at elevated temperatures

  2014cites this paper
• Progress of the synthesis of condensed pyrazole derivatives (from 2010 to mid-2013).

  2014cites this paper
• PDEs as CNS Targets: PDE9 Inhibitors for Cognitive Deficit Diseases

  2014cites this paper
• The Role of Phosphodiesterases in Dopamine Systems governing Motivated Behavior

  2014cites this paper
• Crystal Structures of Phosphodiesterase 9A and Insight into Inhibitor Discovery

  2014cites this paper
• Pharmacological Manipulation of Cyclic Nucleotide Phosphodiesterase Signaling for The Treatment of Neurological and Psychiatric Disorders In The Brain

  2014cites this paper
• PDE4: New Structural Insights into the Regulatory Mechanism and Implications for the Design of Selective Inhibitors

  2014cites this paper
• Recent Results In Phosphodiesterase Inhibitor Development and CNS Applications

  2014cites this paper
• The Use of PDE10A and PDE9 Inhibitors for Treating Schizophrenia

  2014cites this paper
• Emerging targets in neurodegeneration: new opportunities for Alzheimer's disease treatment?

  2013cites this paper
• Cognitive Enhancers (Nootropics). Part 2: Drugs Interacting with Enzymes

  2013cites this paper
• Selective Inhibitors of PDE2, PDE9, and PDE10: Modulators of Activity of the Central Nervous System

  2013cites this paper
• Modulating nitric oxide signaling in the CNS for Alzheimer's disease therapy.

  2013cites this paper
• Structure-based discovery of highly selective phosphodiesterase-9A inhibitors and implications for inhibitor design.

  2012cites this paper
• Application of structure-based drug design and parallel chemistry to identify selective, brain penetrant, in vivo active phosphodiesterase 9A inhibitors.

  2012cites this paper